Alexandra Canonici
Affiliations: | Université de Provence. Section sciences |
Google:
"Alexandra Canonici"Parents
Sign in to add mentor| Frédéric André | grad student | 2009 | Université de Provence. Section sciences | |
| (Effet du microenvironnement sur les molécules d'adhérenceRôle dans la migration cellulaire) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Breen L, Gaule PB, Canonici A, et al. (2020) Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A. Investigational New Drugs |
| Canonici A, Browne AL, Ibrahim MFK, et al. (2020) Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Therapeutic Advances in Medical Oncology. 12: 1758835919897546 |
| Gaynor N, Blanco A, Canonici A, et al. (2020) Abstract 951: The effect of neo-adjuvant chemotherapy on immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients Immunology |
| Eustace A, Roche S, Mukherjee N, et al. (2019) Preclinical evaluation targeting both IGF1R and IR in triple negative breast cancer Annals of Oncology. 30: v782-v783 |
| Canonici A, Ivers L, Conlon NT, et al. (2018) HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Investigational New Drugs |
| Canonici A, Qadir Z, Conlon NT, et al. (2018) The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investigational New Drugs |
| Conlon N, Canonici A, Morgan C, et al. (2018) Abstract P4-03-15: Targeting Src kinase blocks development of afatinib resistance in HER2-positive breast cancer Cancer Research. 78 |
| McDermott MSJ, Canonici A, Ivers L, et al. (2017) Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. International Journal of Oncology |
| Gaynor N, Canonici A, Eustace A, et al. (2016) The effector capacity of peripheral blood mononuclear cells (PBMCs) from HER2+ breast cancer (BC) patients treated with chemotherapy and HER2-targeted therapies (ICORG 10-05) Annals of Oncology. 27: viii5 |
| Canonici A, Conlon N, Morgan C, et al. (2015) Mechanisms of acquired afatinib resistance in HER2-positive breast cancer cells. Journal of Clinical Oncology. 33: 620-620 |